| Question 1: Each radioactive materials license shall develop, document, and implement a radiation protection program commensurate with the scope and extent of licensed
activities and sufficient to ensure compliance with the provisions of this part.
|
| Reference: | 10 CFR 20.1101 Radiation protection programs
https://www.nrc.gov/reading-rm/doc-collections/cfr/part020/part020-1101.html
|
| Choice A: | True. |
| Choice B: | False. |
| Choice C: | Answer C |
| Choice D: | Answer D |
| Question 2: Internal and external monitoring of occupational exposure to radiation is required for
adults like to receive, in 1 year from sources external to the body, a dose in excess of
what percentage of the annual occupational limits?
|
| Reference: | 10 CFR 20.1502 Conditions requiring individual monitoring of external and
internal occupational dose
https://www.nrc.gov/reading-rm/doc-collections/cfr/part020/part020-1502.html
|
| Choice A: | 5% |
| Choice B: | 10% |
| Choice C: | 15% |
| Choice D: | 20% |
| Question 3: The Radiation Protection Program must contain at a minimum:
|
| Reference: | 10 CFR 20.1101 |
| Choice A: | Quality assurance procedures for nuclear medicine equipment. |
| Choice B: | Frequency and documentation of lead apparel testing. |
| Choice C: | Procedures to achieve occupational doses as low as is reasonably achievable. |
| Choice D: | All of the above. |
| Question 4: Radiation safety audits must contain at a minimum:
|
| Reference: | 10 CFR 35.24, Regulatory Guide 8.13, 10 CFR 35.67
|
| Choice A: | Leak testing is performed at the required frequency. |
| Choice B: | Female workers who declare pregnancy document their declaration. |
| Choice C: | The RSO is fulfilling his/her duties. |
| Choice D: | All of the above. |
| Question 5: A Medical Event must be reported:
|
| Reference: | 10 CFR 35.3045 |
| Choice A: | If the actual dose deviates from the prescribed dose by more than 10% for a dose that would have resulted from the prescribed dosage by more than 0.05 Sv effective dose equivalent. |
| Choice B: | For a dose that differs from the prescribed dose when the patient intervenes in the treatment, even if the event does not result in permanent functional damage to an organ. |
| Choice C: | For a dose that exceeds 0.05 Sv effective dose equivalent for an administration of a wrong radioactive drug containing byproduct material. |
| Choice D: | All of the above. |
| Question 6: The NRC requires the following regarding radioactive source security:
|
| Reference: | 10 CFR 37.43 |
| Choice A: | Develop a written security plan. |
| Choice B: | Develop written procedures indicating how the requirements of the security plan will be met. |
| Choice C: | Conduct training to ensure that individuals implementing the security program possess the knowledge, skills, and abilities to carry out their assigned duties and responsibilities effectively. |
| Choice D: | All of the above. |
| Question 7: A licensee’s radiation protection program is required:
|
| Reference: | 10 CFR 20.1101 |
| Choice A: | By regulation in 10 CFR 20, or Agreement State equivalent. |
| Choice B: | Required to follow the ALARA principle. |
| Choice C: | Required to be reviewed annually. |
| Choice D: | All of the above. |
| Question 8: The training and experience requirements for an RSO on a medical use license requires:
|
| Reference: | 10 CFR 35.50 |
| Choice A: | A master’s or doctor’s degree in physics, medical physics, other physical science or engineering from an accredited college or university. |
| Choice B: | Certification from a medical specialty board recognized by the NRC or Agreement State. |
| Choice C: | Has training in the radiation safety, regulatory issues, and emergency procedures for each type of use approved under the license. |
| Choice D: | All of the above. |
| Question 9: The main advantage of an institution having a Type A broad scope radioactive materials license is:
|
| Reference: | Suckow, M.A. and Yates, B. J, Research Regulatory Compliance, Elsevier, Amsterdam, 2015. pp 113-156. |
| Choice A: | The ability to perform both research and clinical procedures without having to amend the radioactive materials license for each new protocol and radionuclide being used, including uses covered under 10 CFR 35.1000. |
| Choice B: | The ability to participate in multi-site clinical trials. |
| Choice C: | To be exempt from licensing fees. |
| Choice D: | To be able to have a single radioactive materials license that covers multiple states. |
| Question 10: 3. A Radioactive Drug Research Committee (RDRC) can approve the research use in human subjects, radioactive drugs that are not approved by the FDA under the following condition(s):
|
| Reference: | 21 CFR 361.1 |
| Choice A: | The research contains no more than 30 subjects. |
| Choice B: | The research is intended to obtain basic information regarding metabolism, physiology, pathophysiology, or biochemistry. |
| Choice C: | The research is intended to evaluate the safety and effectiveness of the radioactive drug in humans. |
| Choice D: | All of the above. |
